Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach
Autosomal dominant polycystic disease (ADPKD) is the most frequent monogenic kidney disease. It causes progressive renal failure, endothelial dysfunction, and hypertension, all of which are strictly linked to oxidative stress (OxSt). Treatment with tolvaptan is known to slow the renal deterioration...
Main Authors: | Matteo Rigato, Gianni Carraro, Irene Cirella, Silvia Dian, Valentina Di Vico, Lucia Federica Stefanelli, Verdiana Ravarotto, Giovanni Bertoldi, Federico Nalesso, Lorenzo A. Calò |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-01-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/2/402 |
Similar Items
-
Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
by: Raina R, et al.
Published: (2022-09-01) -
Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
by: Angela Maria Pellegrino, et al.
Published: (2019-11-01) -
Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy
by: Mai Yamazaki, et al.
Published: (2024-02-01) -
Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
by: Eiji Higashihara, et al.
Published: (2022-02-01) -
The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients
by: Vasiliki Gkika, et al.
Published: (2023-08-01)